Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZW251 · 1 trial · 3 indications
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW251
Number of participants who experienced AEs, adverse events of special interest, or serious adverse events
Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0
Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| ZW251 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZW251 | DRUG | Administered intravenously |
Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis * Pathologically or cytologically confirmed diagnosis of s...
ZW251 is an investigational small molecule being developed for the treatment of advanced solid tumors, including hepatocellular carcinoma, squamous cell non-small cell lung cancer, and germ cell tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ZW251 is being developed by Zymeworks Inc., a biopharmaceutical company traded on the NYSE under the ticker symbol ZYME. The company is conducting clinical trials to evaluate the safety and efficacy of ZW251 in patients with advanced solid tumors.
ZW251 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary activity in advanced solid tumors.
ZW251 is being studied in a Phase 1 clinical trial registered as NCT07164313, titled "A Study of ZW251 in Participants With Advanced Solid Tumors." The trial is currently recruiting and aims to enroll approximately 100 participants across multiple countries, including the United States, Ireland, Japan, Portugal, Spain, and Taiwan.
Yes, ZW251 is being evaluated in a Phase 1 clinical trial that includes patients with hepatocellular carcinoma, as well as squamous cell non-small cell lung cancer and germ cell tumors. The trial is an open-label, uncontrolled study that is actively recruiting participants aged 18 years and older.